Sign In
Buy ATXI
$0.300
+0.0300 (+11.11%)
At Close: Jun 22, 2026
Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)
02:30am, Saturday, 25'th Apr 2026
Insider and Institutional Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 8.6% of
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
08:00am, Monday, 23'rd Feb 2026
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEW
Reviewing Avenue Therapeutics (NASDAQ:ATXI) and Endonovo Therapeutics (OTCMKTS:ENDVD)
01:38am, Thursday, 19'th Feb 2026
Institutional and Insider Ownership 17.3% of Avenue Therapeutics shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Comparatively, 8.6% of Avenue Th
Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI)
02:04am, Saturday, 10'th Jan 2026
Risk and Volatility Avenue Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, indicating that its share
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison
03:17am, Thursday, 25'th Dec 2025
Profitability This table compares NexImmune and Avenue Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NexImmune N/A -534.32% -213.72% A
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
07:00am, Thursday, 06'th Nov 2025
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 14'th Nov 2024
- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulba
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
08:30am, Wednesday, 09'th Oct 2024
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializati
Avenue Therapeutics to Participate in Upcoming Investor Conferences
08:30am, Tuesday, 03'rd Sep 2024
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
04:05pm, Friday, 09'th Aug 2024
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
08:30am, Thursday, 20'th Jun 2024
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializati
Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
08:30am, Wednesday, 15'th May 2024
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Ave
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
08:00am, Monday, 29'th Apr 2024
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
Avenue Therapeutics Announces Reverse Stock Split
07:30am, Wednesday, 24'th Apr 2024
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercializat
